Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 73.03 USD 0.4%
Market Cap: 11.6B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Bio-Techne Corp
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bio-Techne Corp
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Bio-Techne Corp
NASDAQ:TECH
Pre-Tax Income
$225.9m
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
4%
Thermo Fisher Scientific Inc
NYSE:TMO
Pre-Tax Income
$6.8B
CAGR 3-Years
-12%
CAGR 5-Years
11%
CAGR 10-Years
13%
Danaher Corp
NYSE:DHR
Pre-Tax Income
$4.1B
CAGR 3-Years
-17%
CAGR 5-Years
7%
CAGR 10-Years
2%
Mettler-Toledo International Inc
NYSE:MTD
Pre-Tax Income
$955.2m
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
8%
Agilent Technologies Inc
NYSE:A
Pre-Tax Income
$1.5B
CAGR 3-Years
4%
CAGR 5-Years
11%
CAGR 10-Years
21%
IQVIA Holdings Inc
NYSE:IQV
Pre-Tax Income
$1.5B
CAGR 3-Years
17%
CAGR 5-Years
33%
CAGR 10-Years
12%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.6B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.

TECH Intrinsic Value
57.79 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Bio-Techne Corp's Pre-Tax Income?
Pre-Tax Income
225.9m USD

Based on the financial report for Sep 30, 2024, Bio-Techne Corp's Pre-Tax Income amounts to 225.9m USD.

What is Bio-Techne Corp's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
4%

Over the last year, the Pre-Tax Income growth was -21%. The average annual Pre-Tax Income growth rates for Bio-Techne Corp have been 9% over the past three years , 15% over the past five years , and 4% over the past ten years .

Back to Top